Medical Genetics, Department of Molecular Medicine, Sapienza University, San Camillo-Forlanini Hospital, Circonvallazione Gianicolense 87, 00152, Rome, Italy.
Pediatrics Division, Woman-Child Department, San Camillo-Forlanini Hospital, Rome, Italy.
Ital J Pediatr. 2022 Jun 13;48(1):91. doi: 10.1186/s13052-022-01283-w.
In this study, we used the novel DeepGestalt technology powered by Face2Gene (FDNA Inc., MA, USA) in suggesting a correct diagnosis based on the facial gestalt of well-known multiple anomaly syndromes. Only molecularly characterized pediatric patients were considered in the present research.
A total of 19 two-dimensional (2D) images of patients affected by several molecularly confirmed craniofacial syndromes (14 monogenic disorders and 5 chromosome diseases) and evaluated at the main involved Institution were analyzed using the Face2Gene CLINIC application (vs.19.1.3). Patients were cataloged into two main analysis groups (A, B) according to the number of clinical evaluations. Specifically, group A contained the patients evaluated more than one time, while in group B were comprised the subjects with a single clinical assesment. The algorithm's reliability was measured based on its capacity to identify the correct diagnosis as top-1 match, within the top-10 match and top-30 matches, only based on the uploaded image and not any other clinical finding or HPO terms. Failure was represented by the top-0 match.
The correct diagnosis was suggested respectively in 100% (8/8) and 81% (9/11) of cases of group A and B, globally failing in 16% (3/19).
The tested tool resulted to be useful in identifying the facial gestalt of a heterogeneous group of syndromic disorders. This study illustrates the first Italian experience with the next generation phenotyping technology, following previous works and providing additional observations.
在这项研究中,我们使用了由 Face2Gene(美国马萨诸塞州 FDNA 公司)提供的新型 DeepGestalt 技术,根据知名多种异常综合征的面部整体形态来提示正确的诊断。本研究仅考虑了经过分子特征鉴定的儿科患者。
对在主要参与机构接受评估的 19 名患有多种分子证实的颅面综合征(14 种单基因疾病和 5 种染色体疾病)的患者的 19 张二维(2D)图像进行了分析,使用的是 Face2Gene CLINIC 应用程序(版本 19.1.3)。根据临床评估次数,将患者分为两个主要分析组(A、B)。具体来说,组 A 包含接受多次评估的患者,而组 B 包含接受单次临床评估的患者。仅根据上传的图像,不依赖任何其他临床发现或 HPO 术语,算法的可靠性通过其识别正确诊断的能力来衡量,即作为最佳匹配、前 10 名匹配和前 30 名匹配中的 top-1 匹配。top-0 匹配表示失败。
在组 A 和 B 中,正确诊断的比例分别为 100%(8/8)和 81%(9/11),整体失败率为 16%(3/19)。
测试工具在识别综合征性疾病的异质组的面部整体形态方面是有用的。本研究展示了下一代表型技术的首次意大利经验,继先前的工作之后提供了额外的观察结果。